PTC Therapeutics, Inc. (PTCT)

33.78 -0.38 (-1.11%) As of 02:35PM EDT. Market open.

PTC Therapeutics, Inc.

100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000
https://www.ptcbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 988

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.	CEO & Director	1.24M	N/A	1973
Dr. Stuart W. Peltz Ph.D.	Co-Founder, Senior Consultant & Member of Scientific Advisory Board	796.9k	N/A	1960
Dr. Allan Steven Jacobson Ph.D.	Co-Founder, Chairman of Scientific Advisory Board & Independent Director	145k	N/A	1946
Mr. Don Mankoff	Executive Director of Contracts & Deputy General Counsel	N/A	N/A	N/A
Mr. Avraham Adler	Executive Director & Associate General Counsel	N/A	N/A	N/A
Christopher Trotta Ph.D.	Vice President of Biology	N/A	N/A	N/A
Matt Woll	Vice President of Chemistry	N/A	N/A	N/A
Mr. Mark Andrew Rothera	Consultant	549.26k	24.09k	1963

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Corporate Governance

PTC Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 5. The pillar scores are Audit: 7; Board: 2; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.